BDTX Quote, Financials, Valuation and Earnings

Cidara Therapeutics, Inc. has a net margin of 80.77% compared to Black Diamond Therapeutics, Inc.'s net margin of -30201.66%. Black Diamond Therapeutics, Inc.'s return on equity of 18.5% beat Cidara Therapeutics, Inc.'s return on equity of -68.74%.

Black Diamond Therapeutics, Inc. has a consensus price target of $9.25, signalling upside risk potential of 241.33%. On the other hand Cidara Therapeutics, Inc. has an analysts' consensus of $221.50 which suggests that it could grow by 0.45%. Given that Black Diamond Therapeutics, Inc. has higher upside potential than Cidara Therapeutics, Inc., analysts believe Black Diamond Therapeutics, Inc. is more attractive than Cidara Therapeutics, Inc..

Black Diamond Therapeutics, Inc. has a beta of 3.331, which suggesting that the stock is 233.083% more volatile than S&P 500. In comparison Cidara Therapeutics, Inc. has a beta of 1.461, suggesting its more volatile than the S&P 500 by 46.073%.

Black Diamond Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cidara Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Black Diamond Therapeutics, Inc. pays -- of its earnings as a dividend. Cidara Therapeutics, Inc. pays out -- of its earnings as a dividend.

Black Diamond Therapeutics, Inc. quarterly revenues are --, which are smaller than Cidara Therapeutics, Inc. quarterly revenues of --. Black Diamond Therapeutics, Inc.'s net income of -$8.5M is higher than Cidara Therapeutics, Inc.'s net income of -$83.2M. Notably, Black Diamond Therapeutics, Inc.'s price-to-earnings ratio is 7.47x while Cidara Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Black Diamond Therapeutics, Inc. is 2.21x versus 55.23x for Cidara Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Johnson & Johnson has a net margin of 80.77% compared to Black Diamond Therapeutics, Inc.'s net margin of 21.47%. Black Diamond Therapeutics, Inc.'s return on equity of 18.5% beat Johnson & Johnson's return on equity of 33.27%.

Black Diamond Therapeutics, Inc. has a consensus price target of $9.25, signalling upside risk potential of 241.33%. On the other hand Johnson & Johnson has an analysts' consensus of $202.54 which suggests that it could grow by 0.03%. Given that Black Diamond Therapeutics, Inc. has higher upside potential than Johnson & Johnson, analysts believe Black Diamond Therapeutics, Inc. is more attractive than Johnson & Johnson.

Black Diamond Therapeutics, Inc. has a beta of 3.331, which suggesting that the stock is 233.083% more volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.357, suggesting its less volatile than the S&P 500 by 64.296%.

Black Diamond Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 2.54% to investors and pays a quarterly dividend of $1.30 per share. Black Diamond Therapeutics, Inc. pays -- of its earnings as a dividend. Johnson & Johnson pays out 84.8% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Black Diamond Therapeutics, Inc. quarterly revenues are --, which are smaller than Johnson & Johnson quarterly revenues of $24B. Black Diamond Therapeutics, Inc.'s net income of -$8.5M is lower than Johnson & Johnson's net income of $5.2B. Notably, Black Diamond Therapeutics, Inc.'s price-to-earnings ratio is 7.47x while Johnson & Johnson's PE ratio is 19.54x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Black Diamond Therapeutics, Inc. is 2.21x versus 5.33x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Oric Pharmaceuticals, Inc. has a net margin of 80.77% compared to Black Diamond Therapeutics, Inc.'s net margin of --. Black Diamond Therapeutics, Inc.'s return on equity of 18.5% beat Oric Pharmaceuticals, Inc.'s return on equity of -46.08%.

Black Diamond Therapeutics, Inc. has a consensus price target of $9.25, signalling upside risk potential of 241.33%. On the other hand Oric Pharmaceuticals, Inc. has an analysts' consensus of $19.92 which suggests that it could grow by 74.86%. Given that Black Diamond Therapeutics, Inc. has higher upside potential than Oric Pharmaceuticals, Inc., analysts believe Black Diamond Therapeutics, Inc. is more attractive than Oric Pharmaceuticals, Inc..

Black Diamond Therapeutics, Inc. has a beta of 3.331, which suggesting that the stock is 233.083% more volatile than S&P 500. In comparison Oric Pharmaceuticals, Inc. has a beta of 1.324, suggesting its more volatile than the S&P 500 by 32.373%.

Black Diamond Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oric Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Black Diamond Therapeutics, Inc. pays -- of its earnings as a dividend. Oric Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Black Diamond Therapeutics, Inc. quarterly revenues are --, which are smaller than Oric Pharmaceuticals, Inc. quarterly revenues of --. Black Diamond Therapeutics, Inc.'s net income of -$8.5M is higher than Oric Pharmaceuticals, Inc.'s net income of -$32.6M. Notably, Black Diamond Therapeutics, Inc.'s price-to-earnings ratio is 7.47x while Oric Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Black Diamond Therapeutics, Inc. is 2.21x versus -- for Oric Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Puma Biotechnology, Inc. has a net margin of 80.77% compared to Black Diamond Therapeutics, Inc.'s net margin of 16.24%. Black Diamond Therapeutics, Inc.'s return on equity of 18.5% beat Puma Biotechnology, Inc.'s return on equity of 38.49%.

Black Diamond Therapeutics, Inc. has a consensus price target of $9.25, signalling upside risk potential of 241.33%. On the other hand Puma Biotechnology, Inc. has an analysts' consensus of $3.50 which suggests that it could fall by -33.84%. Given that Black Diamond Therapeutics, Inc. has higher upside potential than Puma Biotechnology, Inc., analysts believe Black Diamond Therapeutics, Inc. is more attractive than Puma Biotechnology, Inc..

Black Diamond Therapeutics, Inc. has a beta of 3.331, which suggesting that the stock is 233.083% more volatile than S&P 500. In comparison Puma Biotechnology, Inc. has a beta of 1.177, suggesting its more volatile than the S&P 500 by 17.656%.

Black Diamond Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Puma Biotechnology, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Black Diamond Therapeutics, Inc. pays -- of its earnings as a dividend. Puma Biotechnology, Inc. pays out -- of its earnings as a dividend.

Black Diamond Therapeutics, Inc. quarterly revenues are --, which are smaller than Puma Biotechnology, Inc. quarterly revenues of $54.5M. Black Diamond Therapeutics, Inc.'s net income of -$8.5M is lower than Puma Biotechnology, Inc.'s net income of $8.8M. Notably, Black Diamond Therapeutics, Inc.'s price-to-earnings ratio is 7.47x while Puma Biotechnology, Inc.'s PE ratio is 7.14x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Black Diamond Therapeutics, Inc. is 2.21x versus 1.25x for Puma Biotechnology, Inc.. Usually stocks with elevated PS ratios are considered overvalued.